Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI345 in CLDN18.2-positive solid tumors
NCT05199519Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI345 in gastric cancer (GC) and pancreatic cancer (PC), sponsored by Innovent Biologics. Primary endpoint: Treatment-related adverse events at 2 years. Started Dec 2021; status: completed.
02
Drugs
IBI345
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05199519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199519.